Prospects for new drugs for chronic obstructive pulmonary disease (Q35885857)

10 August 2017

1 reference

title

Prospects for new drugs for chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

10 August 2017

main subject

1 reference

2

Trevor T Hansel

1 reference

10 August 2017

1

Peter J Barnes

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

364

1 reference

10 August 2017

issue

9438

1 reference

10 August 2017

page(s)

985-996

1 reference

10 August 2017

cites work

New treatments for COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Chronic obstructive pulmonary disease: molecular and cellularmechanisms

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Cellular and structural bases of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

New concepts in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Animal models for COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Animal models of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Roles of dopamine signaling in nicotine addiction

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Vaccines against drugs of abuse: a viable treatment option?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Ongoing airway inflammation in patients with COPD who do not currently smoke

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Theophylline: new perspectives for an old drug

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Oxidants/antioxidants and COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

The interrelationship of sputum inflammatory markers in patients with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Exhaled leukotrienes and prostaglandins in COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Expression of Adhesion Molecules and G Proteins in Circulating Neutrophils in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Interleukin-8 receptor antagonists in pulmonary diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Airway Inflammation in COPD Assessed by Sputum Levels of lnterleukin-8*

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

The biology of chemokines and their receptors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Local and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Etanercept: a review of its use in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Phosphodiesterase 4 inhibitors for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Kinase regulation in inflammatory response

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Novel IKK inhibitors: beta-carbolines

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Differential IκB Kinase Activation and IκBα Degradation by Interleukin-1β and Tumor Necrosis Factor-α in Human U937 Monocytic Cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Therapeutic potential of phosphoinositide 3-kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor gamma (PPAR-gamma) binding

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

The role of epidermal growth factor in mucus production

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Severe acute interstitial pneumonia and gefitinib

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A Calcium-Activated Chloride Channel Blocker Inhibits Goblet Cell Metaplasia and Mucus Overproduction

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Pharmacological regulation of the neuronal control of airway mucus secretion

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD)

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Transforming growth factor-beta1 inhibits beta2-adrenoceptor gene transcription

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Inhibitory effects of interferon-gamma on the heterologous desensitization of beta-adrenoceptors by transforming growth factor-beta 1 in tracheal smooth muscle

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A protective role for protease-activated receptors in the airways

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Neutrophils and protease/antiprotease imbalance

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Matrix metalloproteinases. Matrix degradation and more

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Gene therapy progress and prospects: alpha-1 antitrypsin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Thiol-dependent enzymes and their inhibitors: a review

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Effects of all-trans-retinoic acid in promoting alveolar repair

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

A pilot study of all-trans-retinoic acid for the treatment of human emphysema

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Lung epithelial stem cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Exhaled markers of pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(04)17025-6

7 January 2021

10.1016/S0140-6736(04)17025-6

Identifiers

DOI

1 reference

10 August 2017

1 reference